Polycythemia Vera

Show Only Open Trials
1.

Phase 1/2, Open-label, Dose-escalation, Multi-ctr Study to Assess Safety, Tolerability, PK, & PD of Oral NS-018 in Patients w/ Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis

  • Study Status: Open to Enrollment
  • Sponsor: NS Pharma
  • Disease Status and/or Stage: Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
3.

A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

  • Study Status: Open to Enrollment
  • Sponsor: Ely Lilly
  • Disease Status and/or Stage: Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)
4.

Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis

  • Study Status: Open to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
  • Protocol ID: MPD-RC 111
6.

Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis

  • Study Status: Closed to Enrollment
  • Sponsor: Incyte Corporation
  • Disease Status and/or Stage: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
7.

MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

  • Study Status: Closed to Enrollment
  • Sponsor: Myeloproliferative Disorders-Research Consortium
  • Disease Status and/or Stage: Polycythemia Vera (PV)

Top of page